| 张翠萍,汪鹏,李庆,等.多发性骨髓瘤免疫表型特征及其临床意义[J].中国临床保健杂志,2016,(3):228-231. | 
               
			
				| 多发性骨髓瘤免疫表型特征及其临床意义 | 
			 
	       
                | Immunophenotype and its clinical significant of multiple myeloma | 
            
	       
                | 投稿时间:2015-10-08   | 
               
	       
                | DOI:10.3969/J.issn.1672-6790.2016.03.002 | 
               
	       
				| 中文关键词: 多发性骨髓瘤  免疫表型分型  浆细胞  流式细胞术 | 
	        
	       
                | 英文关键词: Multiple myeloma  Immunophenotyping  Plasma Cells  Flow cytometry 〖FL | 
            
	       
                | 基金项目:国家自然科学基金面上项目(81472018);安徽省自然科学基金面上项目(1408085MH145) | 
            
		   
	       
                 | 
            
		   
		   
                | 摘要点击次数: 8143 | 
            
		   
                | 全文下载次数: 7612 | 
            
	       
		| 中文摘要: | 
	       
	      
		|       目的 探讨流式细胞术检测多发性骨髓瘤(MM)的免疫表型特征及其临床意义。方法 应用多参数流式细胞术(MP-FCM),采用CD138/CD45/SSC设门,检测40例MM患者和20例正常献髓者骨髓细胞免疫表型。结果 MM患者抗原异常表达率由高到低分别为CD45dim+/-(95%)、CD81dim+/-(80%)、CD56+(70%)、CD27dim+/-(50%)、CD200++(48%)、CD33+(40%)、CD28++(35%)、CD117+(18%)、CD19+(5%)和CD20+(3%)。CD56+、CD200dim+、CD28dim+在正常浆细胞的表达率分别为10%、10%和5%。结论 应用MP-FCM检测MM细胞免疫表型,可准确地鉴别良恶性浆细胞,有助于MM的诊断、预后判断及靶向治疗。 | 
	       
	     
                | 英文摘要: | 
               
	        
                |       Objective To explore the immunophenotype and its clinical significant of Multiple Myeloma(MM). Methods The immunophenotype of 40 patients with MM and 20 normal volunteers were detected by multiparameter flow cytometry(MP-FCM). Results The abnormality expression of antigens sequence of patients with MM was CD45dim+/-(95%),CD81dim+/-(80%),CD56+(70%),CD27dim+/-(50%),CD200++(48%),CD33+(40%),CD28++(35%),CD117+(18%),CD19+(5%),CD20+(3%) in order. However the positive rations of CD56+, CD200dim+ and CD28dim+ were 10%, 10%and 5%, respectively. Conclusion MP-FCM inspections can accurately discriminate the benign and malignant plasma cell,and provide evidence for prognosis evaluation and targeted therapy. | 
             
		    
                | 
				查看全文
				
				
				      | 
            
	         
	      
                | 关闭  | 
                 
             
           | 
        
         
       
	  
   |     
   
 |